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Complement factors C4 and C3 
are down regulated in response to 
short term overfeeding in healthy 
young men
Caroline Foghmar1,2, Charlotte Brøns2, Katrine Pilely1, Allan Vaag2,3 & Peter Garred1
Insulin resistance is associated with high circulating level of complement factor C3. Animal studies 
suggest that improper complement activation mediates high-fat-diet-induced insulin resistance. 
Individuals born with low birth weight (LBW) are at increased risk of developing insulin resistance. 
We hypothesized that high-fat overfeeding (HFO) increase circulating C3 and induce complement 
activation in a birth weight differential manner. Twenty LBW and 26 normal birth weight (NBW) young 
men were studied using a randomised crossover design. Insulin resistance was measured after a 
control-diet and after 5-days HFO by a hyperinsulinemic-euglycemic-clamp. Circulating C4, C3, ficolins, 
mannose-binding-lectin, complement activation products C3bc, terminal complement complex (TCC) 
and complement activation capacity were determined using turbidimetry and ELISA. HFO induced 
peripheral insulin resistance in LBW individuals only, while both groups had the same degree of 
hepatic insulin resistance after HFO. Viewing all individuals circulating levels of C4, C3, C3bc, TCC and 
complement activation capacity decreased paradoxically along the development of insulin resistance 
after HFO (P = 0.0015, P < 0.0001, P = 0.01, P < 0.0001, P = 0.0002, P < 0.0001, P = 0.0006). Birth 
weight did not influence these results. This might reflect a hitherto unrecognized down-regulatory 
mechanism of the complement system. More human studies are needed to understand the underlying 
physiology and the potential consequences of these findings.
Affecting more than 170 million people worldwide, diabetes constitutes a major threat to human health across the 
world1, with type 2 diabetes (T2D) accounting for more than 90% of all cases2. Individuals born with low birth 
weight (LBW) represent a distinct group of individuals with increased risk of developing insulin resistance and 
T2D due to different molecular and metabolic events during foetal life3–5. We have previously shown that adult 
LBW individuals have multiple metabolic defects and an unfavourable metabolic response to short term high-fat 
overfeeding (HFO) as compared to individuals with normal birth weight (NBW)6, 7.
Subclinical inflammation and improper immune activation may mediate or influence the impact of a high-fat 
diet on the development of insulin resistance8. Particularly the production of pro-inflammatory cytokines by 
dysfunctional adipocytes and infiltration of macrophages in adipose tissue is thought to induce insulin resistance, 
but also other immune cells may be involved8–10. Over the last decades, attention has been drawn to a role of the 
complement system as well. The complement system consists of tree distinct pathways of proteolytic cascades, 
namely the classical, alternative and lectin pathway. These pathways generate C3 convertases efficiently cleaving 
C3 into C3a and C3b11. This leads to the cleavage of C5 into C5a and C5b and the generation of the C5b-9 ter-
minal complement complex (TCC). Both C3a and C5a are anaphylatoxins and mediate a variety of biological 
functions including chemotaxis and inflammatory responses via specific receptors12. Several of the complement 
proteins have been linked to obesity and the metabolic syndrome, and especially a high level of C3 has been 
shown to associate with insulin resistance, obesity and cardiovascular risk factors13–17. Several animal studies sug-
gest that improper complement activation mediates high-fat-diet-induced insulin resistance through the action of 
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the anaphylatoxins18–20, but still it remains unclear whether there is a causal link between complement activation 
and insulin resistance in humans.
In this study we hypothesized that high-fat overfeeding would increase C3 and induce complement activation 
in a potential different manner in people with and without LBW. Accordingly, we investigated circulating levels 
of C3 and the complement activation products C3bc and TCC after a control diet and after short term high-fat 
overfeeding in a group of healthy young men with either NBW or LBW. To further address the impact of HFO 
on the different complement pathways we measured serum levels of C4, lectin pathway initiators and the func-
tional capacity of all three complement pathways separately after a control diet and after HFO. Finally we aimed 
to explore whether the association between C3 and insulin resistance may be due to an association to hepatic or 
peripheral insulin resistance.
Results
Baseline characteristics. When comparing the NBW and LBW subjects before the short term HFO 
the LBW subjects had significantly lower height (P = 0.003) and had increased levels of fasting blood glucose 
(P = 0.01), fasting serum insulin (P = 0.02), and fasting serum C-peptide (P = 0.04) as shown in Table 1 (pre-
viously published data)7. There was no difference in peripheral insulin sensitivity (M-value) between the two 
groups, but LBW subjects had increased hepatic IR index (P = 0.02). The two groups did not have differences in 
serum levels of C4, C3, MBL, Ficolin-1, Ficolin-2, Ficolin-3 or in plasma levels of C3bc and TCC prior to HFO. 
Also, there was no difference in the functional capacity of any of the complement pathways between LBW and 
NBW subjects (Table 1).
Metabolic response to short term high-fat overfeeding. The metabolic response to five days of 
HFO is shown in Table 1 and has previously been described in details7. In short, the fasting blood glucose level 
increased significantly in the NBW (P = 0.0005) as well as the LBW individuals (P = 0.05) in response to HFO. 
In the NBW subjects there was an additional increase in fasting serum insulin (P = 0.02) and fasting serum 
C-peptide (P = 0.01) levels. The LBW individuals became significantly more insulin resistant in peripheral tissue 
in response to HFO (P = 0.03) whereas the NBW individuals selectively developed hepatic insulin resistance 
(P = 0.0002).
Effects of short term high-fat overfeeding on serum levels of C4, C3 and lectin pathway initia-
tors and plasma level of albumin. The serum levels of C4 and C3 decreased significantly (P = 0.0015 and 
P < 0.0001, respectively) in response to short term HFO when looking at the whole population (Table 2, Fig. 1), 
and also when looking at the NBW and LBW separately (Table 1). Birth weight category did not significantly 
influence the size of the decrease (data not shown). Serum concentrations of the lectin pathway initiators did not 
NBW (n = 25) LBW (n = 18)
CON HFO CON HFO
Age (years) 24.6 ± 1.1 24.7 ± 1.1 24.2 ± 0.5 24.2 ± 0.5
Height (m) 1.83 ± 0.07 — 1.77 ± 0.05## —
Weight (kg) 78.4 ± 9.3 78.6 ± 9.7 77.1 ± 11.3 77.1 ± 11.4
BMI (kg/m2) 23.3 ± 2.4 23.3 ± 2.5 24.6 ± 3.8 24.6 ± 3.8
Fasting blood glucose (mmol/l) 4.59 ± 0.47 5.05 ± 0.40*** 4.97 ± 0.48# 5.18 ± 0.34*
Fasting serum insulin (pmol/l) 30.9 ± 14.7 43.4 ± 29.2* 41.7 ± 14.6# 44.7 ± 21.9
Fasting serum C-peptide (pmol/l) 408 ± 146 529 ± 260* 492 ± 116# 539 ± 172
M value (mg/kg FFM/min) 13.7 ± 2.3 13.3 ± 3.3 13.5 ± 3.2 11.9 ± 3.6*
Hepatic insulin-resistance index 68.7 ± 34.1 113.7 ± 61.5*** 102.3 ± 50.8# 108.7 ± 55.5
Serum C4 (mg/ml) 0.22 ± 0.05 0.20 ± 0.06** 0.24 ± 0.05 0.22 ± 0.06*
Serum C3 (mg/ml) 1.12 ± 0.15 1.04 ± 0.13*** 1.14 ± 0.12 1.05 ± 0.14**
Serum MBL (ng/ml) 941 ± 920 920 ± 898 1124 ± 1149 1083 ± 1286*
Serum Ficolin-1 (µg/ml) 0.32 ± 0.10 0.33 ± 0.14 0.29 ± 0.07 0.30 ± 0.08
Serum Ficolin-2 (µg/ml) 6.38 ± 2.15 6.21 ± 2.03 6.49 ± 1.85 6.24 ± 2.10
Serum Ficolin-3 (µg/ml) 27.1 ± 9.0 25.6 ± 7.6 26.4 ± 7.7 27.6 ± 6.6
Plasma Albumin (g/l) 44.9 ± 2.3 44.6 ± 2.6 43.8 ± 1.9 43.7 ± 2.2
Plasma C3bc (AU/ml) 8.56 ± 2.25 7.75 ± 2.66 8.32 ± 2.11 6.54 ± 1.45***
Plasma TCC (AU/ml) 0.52 ± 0.09 0.45 ± 0.20** 0.51 ± 0.13 0.35 ± 0.10***#
C3bc/C3-ratio 7.71 ± 1.92 7.46 ± 2.41 7.30 ± 1.70 6.24 ± 1.11*
Classical pathway TCC (%) 97.4 ± 7.7 92.4 ± 7.6** 100.7 ± 6.0 95.2 ± 7.3*
Alternative pathway TCC (%) 94.5 ± 11.0 87.5 ± 10.1** 98.5 ± 10.4 89.2 ± 9.6***
Lectin pathway TCC (%) 75.3 ± 47.8 67.8 ± 49.7* 74.4 ± 56.1 63.5 ± 56.2**
Table 1. Subject characteristics of NBW and LBW subjects (CON) and after high-fat overfeeding (HFO). Data 
are means ± SD. AU, arbitrary units; CON, control diet; HFO, High-fat overfeeding; TCC, terminal complement 
complex. NBW vs. LBW: #P ≤ 0.05, ##P ≤ 0.01. CON vs. HFO diet: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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change in response to HFO in the whole population, but in LBW subjects MBL decreased significantly after HFO 
(P = 0.03). Plasma concentration of albumin did not change significantly after HFO in the whole population, or 
in NBW or LBW subjects.
Effects of short term high-fat overfeeding on complement activation. Plasma level of C3bc, 
reflecting C3 activation, decreased significantly (P = 0.01) in response to HFO when looking at the whole popula-
tion (n = 43) (Fig. 1) and LBW (P = 0.0008) but not in NBW (Table 1). Plasma TCC decreased significantly after 
HFO when analysing the whole population (n = 43) (Fig. 1) but also when analysing NBW and LBW subjects sep-
arately (p = 0.002 and p = 0.0004, respectively) (Table 1). The C3bc/C3-index decreased significantly after HFO 
when looking and the whole population (Table 2) as well as in LBW subjects (P = 0.03 and P = 0.02, respectively), 
but remained unchanged after HFO in the NBW subjects (Table 1).
Effects of short term high-fat overfeeding on complement activation capacity. When looking 
at all individuals (Table 2), the capacity of the classical, alternative and lectin pathway decreased significantly in 
response to HFO (P = 0.0002, P < 0.0001 and P = 0.0006, respectively). This significant decrease persisted when 
viewing the two subgroups separately (Table 1). Birth weight was not related to the size of the complement acti-
vation decrease (data not shown).
Reversibility of the complement dampening effect of short term high-fat overfeeding. In order 
to examine if the complement dampening effect of HFO was transient or more profound we found, in the 24 
individuals who received the control diet first followed by the HFO diet 6–8 weeks after, that C4, C3 and TCC 
decreased significantly after HFO (p = 0.0004, p < 0.0001 and p = 0.0008, respectively) (Fig. 2A,C and G), as did 
the functional capacity of the classical, alternative and lectin pathway (P = 0.0004, P < 0.0001 and P = 0.0027 
respectively) (Fig. 3A,C,E). Viewing the 19 subjects whom received HFO first followed by the control diet 6–8 
weeks after, C4 and C3 levels did not increase significantly after the control diet, although a trend was seen for 
C3 (P = 0.066) (Fig. 2D). C3bc and TCC increased significantly after the control diet (p = 0.026 and p = 0.0045, 
respectively) (Fig. 2F and H). The functional capacity of the classical, lectin and alternative pathway did not 
increase significantly, but a trend towards increase was seen (P = 0.069, P = 0.1091 and P = 0.058, respectively) 
(Fig. 3B,D and F).
Association of hepatic insulin resistance with serum levels of C4, C3 and lectin pathway ini-
tiators. Taking all subjects into account (Table 3) we found a positive correlation between serum level of 
C3 and hepatic insulin resistance index (hepatic IR-index) on the control diet (CON) and after HFO (CON: 
rs = 0.53 P = 0.0002, HFO: rs = 0.43 P = 0.004). C4 was positively correlated with hepatic insulin resistance, 
but only on the control diet (rs = 0.36 P = 0.02). When looking at the two subgroups (Table 3), serum level of 
C3 was still significantly correlated with hepatic insulin resistance in the NBW subjects regardless of the diet 
(CON: rs = 0.51 P = 0.01, HFO: rs = 0.41 P = 0.04). In LBW subjects C3 was correlated with hepatic insulin 
resistance on the control diet (rs = 0.58 P = 0.01), and the same trend was seen after HFO but was not significant 
(rs = 0.41 P = 0.09).
n (43)
CON HFO
Reference 
range
Serum C4 (mg/ml) 0.23 ± 0.05 0.21 ± 0.06** (0.13–0.39)#
Serum C3 (mg/ml) 1.13 ± 0.14 1.04 ± 0.14*** (0.81–1.57)#
Serum MBL (ng/ml) 1018 ± 1013 988 ± 1066 —##
Serum Ficolin-1 (µg/ml) 0.31 ± 0.09 0.32 ± 0.12 (0.01–1.89)36
Serum Ficolin-2 (µg/ml) 6.42 ± 2.01 6.22 ± 2.04 (1.0–12.2)37
Serum Ficolin-3 (µg/ml) 27.0 ± 8.4 26.4 ± 7.2 (3–54)38
Plasma Albumin (g/l) 44.4 ± 2.2 44.2 ± 2.4 (40–53)
Plasma C3bc (AU/ml) 8.46 ± 2.17 7.25 ± 2.29* (2.9–9)###
Plasma TCC (AU/ml) 0.52 ± 0.11 0.41 ± 0.18*** (0.3–0.7)###
C3bc/C3-ratio 7.54 ± 1.82 6.95 ± 2.05* —
Classical pathway TCC (%) 98.8 ± 7.2 93.6 ± 7.5*** (69–129)####
Alternative pathway TCC (%) 96.2 ± 10.8 88.2 ± 9.8*** (30–113)####
Lectin pathway TCC (%) 74.9 ± 50.8 66.0 ± 51.9*** (0–125)####
Table 2. Impact of short term high-fat overfeeding on serum levels of C4, C3 and lectin pathway initiators, 
plasma levels of albumin and complement activation products C3bc and TCC and complement activation 
capacity in all individuals who completed the overfeeding challenge. Data are means ± SD. AU, arbitrary 
units; CON, control diet; HFO, High-fat overfeeding; TCC, terminal complement complex. CON vs. HFO 
diet: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. #95 Percentile range from the manual of the SPAplus complement 
kit. ##Reference range left out due to the wide variations among healthy individuals. ###Unpublished internal 
laboratory reference ranges. ####± 2 SD reference range from the manual of WIESLAB Complement system 
screen.
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Association of peripheral insulin-resistance with serum levels of C4, C3 and lectin pathway ini-
tiators. The correlations of the different complement factors with peripheral insulin sensitivity (M-value) 
are shown in Table 4. When looking at the whole study population (n = 43), Ficolin-1 was negatively corre-
lated to M-value after HFO (rs = −0.38 P = 0.01). This finding persisted when analysing the NBW-subjects after 
HFO (rs = −0.42 P = 0.03), but not in LBW subjects. In LBW subjects Ficolin-3 was negatively correlated to 
M-value, although only on the control diet (rs = −0.50 P = 0.04). C4 and C3 did not correlate with peripheral 
insulin-resistance in the whole group or any of the subgroups regardless of the diet.
Discussion
Insulin resistance has consistently been associated with a high serum level of C3 in a potentially causal man-
ner13–16. However, the physiological mechanisms remain unclear. In this study we aimed to investigate whether 
insulin resistance induced by a high-fat diet might influence the complement system, and particularly circulating 
C3 level and complement activation. Our short term HFO intervention is relevant as it resembles commonly 
occurring feast periods in different cultures all over the world, and HFO over longer periods is one of the most 
important risk factors of obesity, insulin resistance and T2D.
We hypothesized that our short term HFO challenge would increase serum level of C3 and induce comple-
ment activation possibly affecting the development of insulin resistance. However, we found a significant decrease 
in serum levels of C4 and C3 alongside the development of insulin resistance in response to short term HFO. In 
line with these findings, we found a significant decrease in the activation capacity of all three complement path-
ways after HFO. To our knowledge, this is the first report to describe a short term HFO diet-induced decrease in 
circulating C4 and C3 in humans.
In contrast to our hypothesis of an increase in complement factors and complement activation during HFO, 
complement activation products C3bc and TCC and C3bc/C3 ratio decreased paradoxically in the whole group 
after HFO. Accordingly, our results do not directly support the idea that improper complement activation influ-
ences the development of insulin resistance in response to overly rich nutrition in humans at least in an acute 
setting.
The randomised crossover design of this study (Fig. 4) allowed us to examine the reversibility of this comple-
ment dampening effect of short term HFO, by comparing the 24 subjects who were randomised to receive the 
control diet 6–8 weeks before the HFO diet with the 19 subjects who were randomised to receive the HFO diet 
before the control diet (Figs 2 and 3). Interestingly, the comparison showed that the impact of HFO on C4 was not 
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Figure 1. Circulating C4, C3, C3bc and TCC in response to overfeeding. Serum levels of C4 and C3 and plasma 
level of complement activation products C3bc and TCC after a control diet and after overfeeding in all subjects 
(n = 43). Data are reported as scatter-dot plots and medians. Paired two-tailed t-test p-values represent the 
difference in serum/plasma concentration before and after overfeeding. AU, arbitrary units; CON, control diet; 
HFO, high-fat overfeeding.
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Figure 2. Reversibility of the impact of short term high-fat overfeeding on circulating C4, C3, C3bc and TCC. 
Comparison of the subjects that received the control diet first (n = 24) and the high-fat overfeeding diet 6–8 
weeks after (diagram A,C,E,G), with the subjects that received the high-fat overfeeding first (n = 19) and the 
control diet 6–8 weeks after (diagram B,D,F,H). Data are reported as means with 95% CI. Paired two-tailed 
t-test p-values represent the difference in serum/plasma concentration of the different complement factors after 
control diet vs. after overfeeding. Please note the Y-axis benchmark in diagram (A and B) is 0.16, in diagram (C 
and D) 0.5, and in diagram (E,F,G and H) 0. AU, arbitrary units; CON, control diet; HFO, high-fat overfeeding; 
1 = first study period; 2 = second study period.
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Figure 3. Reversibility of the impact of short term high-fat overfeeding on complement activation capacity. 
Comparison of the subjects that received the control diet first (n = 24) and the high-fat overfeeding diet 6–8 
weeks after (diagram A,C,E), with the subjects that received the high-fat overfeeding first (n = 19) and the 
control diet 6–8 weeks after (diagram B,D,F). Data are reported as means with 95% CI. Paired two-tailed t-test 
p-values represent the difference in functional complement activation capacity of the different complement 
pathways after control diet vs. after overfeeding. Please note the Y-axis benchmark in diagram (A and B) is 70, 
in diagram (C and D) 60, and in diagram (E and F) 0. CON, control diet; HFO, high-fat overfeeding; 1 = first 
study period; 2 = second study period.
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significantly reversible after 6–8 weeks. C3bc and TCC increased significantly in the group receiving HFO before 
the control diet, indicating a reversible effect of HFO on complement activation. When looking at the impact of 
HFO on C3 there is a trend towards reversibility as well (Fig. 2D), and the same trend is seen for the impact of 
HFO on the functional complement activation capacity (Fig. 3). Thus our observations suggest that the comple-
ment dampening effect of short term HFO is in general a transient phenomenon.
There are several potential mechanistic explanations for the observed decrease in serum C4 and C3 levels in 
response to HFO. First, it is possible that HFO stresses the liver and reduce its ability to produce complement fac-
tors due to ectopic fat accumulation. We have previously shown that HFO induces hepatic insulin resistance and 
increases circulating liver enzyme ASAT, which is indeed an indication of a stressed liver6, 7. With the liver being 
the primary site for C4, C3, Ficolin-2, Ficolin-3 and MBL synthesis21, 22, a decrease in liver function could explain 
decreased circulating levels of these proteins and consequently a decreased capacity of complement activation. 
However, we did not find a decrease in the circulating levels of Ficolin-2, Ficolin-3, MBL or albumin also pro-
duced in the liver. Therefore our results do not indicate that short term HFO has a general impact on liver protein 
synthesis, and a diet-induced inhibition of hepatic biosynthesis specifically of C4 and C3 has to our knowledge 
not been reported previously.
Another explanation could be that hyperinsulinaemia in the overfed subjects promotes a down regulation of 
C4 and C3. Continuous insulin infusion has previously been shown to down regulate circulating C3 in severely 
burned children23, and insulin is well known to exhibit various systemic anti-inflammatory effects in humans 
including suppression of pro-inflammatory cytokines as well as induction of anti-inflammatory mediators24–27. 
A scenario could be that hyperinsulinaemia may influence transcription factors relevant for hepatic C4 and C3 
synthesis.
These possible explanations of the decrease in C4 and C3 levels are not mutually exclusive, and irrespective 
of the underlying mechanisms, a key question is whether diet-induced lowering of complement proteins may be 
harmful if occurring in for instance elderly and more immunocompromised people and/or with longer expo-
sure to overfeeding. Indeed, the complement system protects against invading microorganisms, and complement 
defects have various different consequences including recurrent bacterial infections, autoimmune manifestations 
and renal disorders, depending on the specific complement defect28. For instance, we cannot exclude the possi-
bility that the changes in the gut microbiota during high-fat feeding as seen in mice and insulin resistant humans 
could be triggered by changes in the complement system29.
The LBW group was included in the study because of their known increased risk of developing insulin resist-
ance and T2D3–5, 7. However, we did not find any difference between the NBW controls and the LBW subjects 
Parameter
ALL (n = 43) NBW (n = 25) LBW (n = 18)
CON HFO CON HFO CON HFO
rs p value rs p value rs p value rs p value rs p value rs p value
C4 (mg/ml) 0.36 0.02* 0.08 0.59 0.34 0.09 0.03 0.89 0.17 0.49 0.18 0.46
C3 (mg/ml) 0.53 0.0002*** 0.43 0.004** 0.51 0.01** 0.41 0.04* 0.58 0.01* 0.41 0.09
MBL (ng/ml) −0.10 0.54 −0.11 0.46 −0.42 0.04* −0.06 0.002** 0.30 0.22 0.42 0.08
Ficolin1 (µg/ml) 0.24 0.13 0.20 0.19 0.37 0.07 0.12 0.55 0.18 0.47 0.23 0.37
Ficolin2 (µg/ml) 0.14 0.38 0.21 0.18 0.06 0.78 0.23 0.27 0.32 0.19 0.23 0.40
Ficolin3 (µg/ml) 0.17 0.27 0.17 0.29 0.26 0.21 0.14 0.50 0.24 0.35 0.26 0.32
Table 3. Associations between hepatic IR-index and serum levels of C4, C3 and lectin pathway initiators. 
Spearman’s correlations (rs) between hepatic IR-index (a measure of hepatic insulin resistance) and serum 
levels of C4, C3 and lectin pathway initiators. Statistical significance assumed for values *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001. CON, control diet; HFO, high-fat overfeeding; NBW, normal birth weight individuals; LBW, low 
birth weight individuals; ALL, NBW+ LBW individuals.
Parameter
ALL (n = 43) NBW (n = 25) LBW (n = 18)
CON HFO CON HFO CON HFO
rs p value rs p value rs p value rs p value rs p value rs p value
C4 (mg/ml) −0.10 0.51 −0.14 0.36 −0.06 0.76 −0.32 0.11 −0.12 0.63 0.17 0.51
C3 (mg/ml) −0.12 0.46 −0.16 0.31 −0.12 0.55 −0.29 0.16 −0.06 0.81 −0.03 0.90
MBL (ng/ml) −0.11 0.48 0.08 0.63 −0.23 0.27 −0.02 0.93 −0.25 0.32 0.13 0.62
Ficolin1 (µg/ml) 0.13 0.40 −0.38 0.01* 0.04 0.85 −0.42 0.03* −0.25 0.32 −0.30 0.22
Ficolin2 (µg/ml) −0.29 0.06 −0.02 0.87 −0.12 0.56 −0.19 0.37 −0.13 0.60 −0,05 0,84
Ficolin3 (µg/ml) −0.16 0.31 −0.24 0.13 0.23 0.26 −0.03 0.90 −0.50 0.04* −0.32 0.21
Table 4. Associations between M-value and serum levels of C4, C3 and lectin pathway initiators. Spearman’s 
correlations (rs) between M-value (an inverse measure of insulin resistance) and serum levels of C4, C3 and 
lectin pathway initiators. Statistical significance assumed for values *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
CON, control diet; HFO, high-fat overfeeding; NBW, normal birth weight individuals; LBW, low birth weight 
individuals; ALL, NBW+ LBW individuals.
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regarding circulating levels of C4, C3, C3bc, TCC or lectin pathway initiators on the control diet. Neither did 
we find any consistent differences between the two groups in the decrease of C4 or C3 levels, or in the comple-
ment activation capacity in response to HFO. Circulating C3bc and the C3bc/C3 ratio decreased significantly 
in the LBW subjects in response to HFO when compared to NBW subjects, where C3bc and the C3bc/C3 ratio 
remained unchanged after overfeeding. While this small difference between groups may have occurred as the 
result of a chance finding, we demonstrated that HFO did not induce complement activation detectable in plasma 
in any of the two groups. Thus, our data do altogether not support the idea that LBW individuals‘ predisposition 
to insulin resistance, T2D and cardiovascular disease may occur as a result of increased complement system 
activation.
Another novel finding of the current study is the selective association between plasma C3 levels and hepatic 
but not peripheral insulin resistance. We used the gold standard hyperinsulinemic euglycemic clamp technique 
enabling us to distinguish between hepatic and peripheral insulin resistance. Previous studies have reported asso-
ciations between high circulating levels of C3 and insulin resistance using the more indirect homeostasis model 
assessment of insulin resistance (HOMA-IR)13–16. HOMA-IR predominantly reflects hepatic insulin resistance 
indirectly supporting our results. The LBW subjects did not show a significant association of C3 with hepatic 
insulin resistance after HFO, but an obvious trend was seen (rs = 0.41 P = 0.09) and the lack of significance is 
possibly to be due to the small sample size.
Our finding that insulin resistance induced experimentally by short term HFO was not associated with any 
detectable complement activation in serum is an argument against the hypothesis that insulin resistance may be 
induced by complement activation. However, a limitation of our study is that we measured complement acti-
vation using ELISA on plasma. Over the last decades it has become clear that adipose tissue is a major source 
of complement products such as C3 and proximal components of the alternative pathway, factor B and factor 
D (adipsin)30–32. The role of complement in adipose tissue is only scarcely explored. Complement is thought 
to promote peripheral insulin resistance via stimulation of macrophage infiltration and activation in adipose 
tissue by the anaphylatoxins C3a and C5a. Activated adipose tissue macrophages are well known to produce 
pro-inflammatory cytokines, like IL-6 and TNF-∝, that inhibits the insulin receptor and thereby induce insulin 
resistance10. On the other hand C3 and its cleavage product C3a desArg are now recognized to have important 
roles in lipid storage and metabolism. C3a desArg, like insulin, stimulates FFA and glucose uptake in adipocytes, 
and it is generated in proportion to the total amount of C333. Very recently the anaphylatoxins C3a and C5a 
have been shown to have insulin-like properties as well20. A recent study by Lo et al. showed that anaphylatoxin 
C3a improves insulin secretion from β-cells in diabetic mice34. Thus more and more evidence supports a dual 
role of the complement system in adipose tissue in relation to obesity, insulin resistance and T2D. It is therefore 
possible that local complement activation within the adipose tissue may affect insulin sensitivity of the adipose 
tissue and contribute to the reduced peripheral insulin resistance observed in the LBW subjects after overfeed-
ing. Nevertheless, such a local change in complement activity may not be detected when performing ELISA on 
plasma, and thus further studies with direct assessment of local complement activation are needed before drawing 
to the conclusion that complement activation does not contribute to the development of high-fat-diet-induced 
insulin resistance.
Figure 4. Study design. Flow chart showing the randomised crossover design of the study. The 46 participants 
were randomised to receive either the control diet before the first examination and high-fat overfeeding before 
the second examination or to receive the high-fat overfeeding before the first examination and the control diet 
before the second examination. The two study periods were separated by a 6–8 weeks wash out period. One 
participant experienced discomfort during the first clamp examination; why it was terminated and not repeated. 
This participant was excluded. Two participants did not complete the overfeeding intervention and were 
therefore excluded. CON, control diet; HFO, high-fat overfeeding; LBW, low birth weight; NBW, normal birth 
weight.
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In conclusion, we have shown that short term high-fat overfeeding induce a decrease in serum levels of C4 
and C3 in healthy young men, affecting their complement activation capacity significantly. Birth weight asso-
ciated risk of developing insulin resistance did not influence these findings. We have furthermore documented 
that serum level of C3 is positively associated with hepatic, but not peripheral insulin resistance in healthy young 
men. Further studies are required to understand the mechanisms underlying - as well as potential consequences 
of these findings.
Research Design and Methods
Study population. As previously described6, 7, 46 healthy male volunteers 23–27 years of age were recruited 
from the Danish Medical Birth Register. Twenty males were born with a low birth weight (BW ≤ 10th percen-
tile) (2688 ± 269 g), and 26 age- and BMI-matched controls were born with a normal birth weight (BW between 
50–90th percentile) (3893 ± 207 g). All were singletons and born at term in the area of Copenhagen. Exclusion 
criteria included family history of diabetes (in 2 generations), body mass index (BMI) greater than 30, and high 
physical activity level (>10 h of exercise per week). None of the participants had known illness or took medica-
tions known to affect the study outcome. Informed consent was obtained from all participants, and the protocol 
was in accordance with The Helsinki Declaration and approved by the ethical committee for Copenhagen County 
(KA-03129-gm).
Study design. The data presented here are a part of a larger study investigating the impact of LBW and HFO 
on T2D pathophysiology and some data have thus been published previously, but are included here to provide 
the background of the current findings6, 7. All participants were examined twice in a randomised order; after a 
control period (CON) and after 5 days high-fat overfeeding (HFO). 25 subjects had their first examination after a 
control diet and 21 subjects had their first examination after a HFO diet (Fig. 4). Prior to each examination, were 
the participants standardized for 5 days with regards to diet, exercise and alcohol intake and the CON experiment 
was optimized even further by providing all foods (30% fat) for 3 days before the clamp examination. The HFO 
diet was provided to the participants and consisted of 60% fat and contained 50% more calories than individually 
required7. The requirement was multiplied by a factor of 1.5 corresponding to a low physical activity level. The 
two study periods were separated by a 6–8 weeks wash-out-period and subjects were asked to remain weight sta-
ble during this period. Participants were expected to eat all of the provided food, however to ensure compliance 
potential leftovers were collected, weighed and subtracted from the total energy intake. Two LBW participants did 
not complete the overfeeding intervention and one NBW experienced discomfort during the first clamp examina-
tion; therefore, it was terminated and not repeated. These 3 participants were therefore excluded.
Investigation of insulin-resistance. Following the CON and the HFO period, insulin sensitivity and 
hepatic glucose production were measured by a 3-hour hyperinsulinemic euglycemic-clamp combined with 
a continuous infusion of tritiated 3-3H-glucose. In short, an insulin-infusion of 80 mU m−2 min−1 was used 
throughout the clamp and to maintain euglycemia of 5 mmol/l. A variable infusion of glucose enriched with 
tritiated 3-3H-glucose was applied. The insulin-stimulated glucose disposal rate (M-value) and hepatic insulin 
resistance index (hepatic IR-index) were calculated as described previously6, 7.
Serum concentration of C4, C3 and lectin pathway initiators. Serum concentrations of C4 and C3 
were measured using an automated turbidimetric protein analyser (SPAPLUS®, The Binding Site group LDT, 
Birmingham, UK). The used antibodies were sheep polyclonal antibodies, raised against human C3c and human 
C4 respectively (The Binding Site group LDT, Birmingham, UK). MBL and ficolin serum concentrations were 
determined by established ELISA-based methods using antibodies produced in our own laboratories35–38. In 
short, microtiter plates were coated with one of the following monoclonal antibodies: anti-MBL (HYB-131-1), 
anti-Ficolin-1 (FCN166), anti-Ficolin-2 (FCN216), or anti-Ficolin-3 (FCN334), in phosphate-buffered saline 
(PBS). The plates were incubated overnight at 4 °C. Diluted serum samples were applied to the plates and incu-
bated for three hours. A standard dilution series of pooled human serum with known concentration of MBL, 
Ficolin-1, Ficolin-2 and Ficolin-3 was added to each assay. Plates were incubated with biotinylated antibodies: 
monoclonal anti-MBL (HYB-131-1), polyclonal anti-Ficolin-1 (Hycult), monoclonal anti-Ficolin-2 (FCN219), 
and monoclonal anti-Ficolin-3 (FCN334) overnight at 4 °C. HRP-conjugated streptavidin was added to the wells 
and incubated for one hour. Plates were washed in PBS-tween between every step. At last o-phenylenediamine 
dihydrochloride (OPD) substrate solution containing H2O2 was added to the wells. Plates were developed for 
15 min. Addition of sulphuric acid was used to terminate the enzymatic reaction and the optical density was 
measured at 490 nm (ELx808™ Absorbance Microplate Reader, BioTek, Vermont, USA).
Assays for complement activation markers. The complement activation products C3bc and TCC were 
measured in EDTA-plasma samples by established ELISA-based methods using antibodies produced in our own 
laboratories39–41. In short, microtiter plates were coated with monoclonal antibodies: anti-C3bc (clone BH6) or 
anti-C9 (clone aE11) in PBS. The plates were incubated overnight at 4 °C. Diluted plasma samples were applied 
to the plates and incubated for one hour at 4 °C in the C3bc-assay and one hour at room temperature in the 
TCC-assay. A standard dilution series of pooled zymosan activated serum was added to each assay. Plates were 
incubated with biotinylated antibodies: polyclonal anti-C3c (DAKO, Q0368) or monoclonal anti-C6 (clone 9C4) 
for one hour. HRP-conjugated streptavidin was added to the wells and incubated for one hour. Plates were washed 
in PBS-tween between every step. At last plates were developed with TMB One (Kem-En-Tec Diagnostics) for 
15 min. Addition of sulphuric acid was used to terminate the enzymatic reaction and the optical density was 
measured at 450 nm (ELx808™ Absorbance Microplate Reader, BioTek, Vermont, USA). A C3bc/C3-index was 
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calculated, allowing us to normalize the C3bc concentration in relation to the total concentration of C3, so that 
variations in C3 concentration did not influence the assessment of the complement activation analysis.
Functional capacity of the classical, alternative and lectin pathway. The complement activation 
capacity of the classical, alternative and lectin pathway was determined using an established semi quantitative 
ELISA-assay (WIESLAB® Complement System Screen COMPL 300, Euro Diagnostica, Malmö, Sweden). In brief: 
wells were precoated with specific activators of the classical, alternative and lectin pathway. Patient serum was 
diluted in different buffers containing specific inhibitors ensuring that only the respective pathway was activated. 
A positive control (PC) and a negative control (NC) were added to each assay. The plates were incubated with the 
diluted serum samples and diluted controls for one hour and then washed. A specific alkaline phosphatase labe-
led antibody detecting C5b-9 was added to all the wells. Plates were incubated for half an hour and subsequently 
washed. At last a phosphatase substrate solution was added to the wells and incubated for half an hour. The optical 
density was measured at 405 nm and the complement activation capacity in % was calculated as follows: (sample 
- NC)/(PC - NC).
Statistics. All data were analysed for normality using Shapiro-Wilk normality test and appropriate statistical 
tests was applied. NBW and LBW individuals were compared using an unpaired t-test, or a Mann-Whitney test 
when data were not normally distributed. When looking at the effect of overfeeding a two-tailed paired t-test was 
applied on normally distributed data, while a Wilcoxon test was used on non-parametric data. To determine the 
association of peripheral and hepatic insulin-resistance with serum levels of C3, C4 and lectin pathway initiators 
we used the Spearman Rank correlation on all data. Statistical significance was assumed for P-values ≤ 0.05. All 
analyses were performed using GraphPad Prism 4, San Diego, California, USA.
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